Urinary N-Acetyl-β-d-Glucosaminidase (NAG) Levels and Risk of Cardiovascular Events in Diabetic Patients

References

• Hosh-Swaby OR, Goodman SG, Leiter LA, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418–435. doi:10.1016/S2213-8587(20)30038-3
   PubMed Web of Science ®Google Scholar
• Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation. 2020;141(5):407–410.
   PubMed Web of Science ®Google Scholar
• Wanner C, Lachin JM, Inzucchi SE, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119–129. doi:10.1161/CIRCULATIONAHA.117.028268
   PubMed Web of Science ®Google Scholar
• Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113(25):2943–2946. doi:10.1161/CIRCULATIONAHA.106.176583
   PubMed Web of Science ®Google Scholar
• Mulè G, Cottone S, Cusimano P, et al. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension. Am J Hypertens. 2009;22(10):1041–1047. doi:10.1038/ajh.2009.132
   PubMed Web of Science ®Google Scholar
• Ishimura E, Taniwaki H, Tsuchida T, et al. Urinary albumin excretion associated with arterial wall stiffness rather than thickness in type 2 diabetic patients. J Nephrol. 2007;20(2):204–211.
   PubMed Web of Science ®Google Scholar
• Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 1996;19(11):1243–1248. doi:10.2337/diacare.19.11.1243
   PubMed Web of Science ®Google Scholar
• Willeit P, Tschiderer L, Allara E, et al; PROG-IMT and the Proof-ATHERO Study Groups. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation. 2020;142(7):621–642. doi:10.1161/CIRCULATIONAHA.120.046361
   PubMed Web of Science ®Google Scholar
• Mulè G, Cottone S, Vadalà A, et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med. 2004;256(1):22–29. doi:10.1111/j.1365-2796.2004.01338.x
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Y, Xu M, et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J Clin Endocrinol Metab. 2010;95(11):5122–5128. doi:10.1210/jc.2010-0544
   PubMed Web of Science ®Google Scholar
• Kim SR, Lee YH, Lee SG, et al. Urinary N-acetyl-β-D-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes. Medicine. 2016;95(27):e4114. doi:10.1097/MD.0000000000004114
   PubMed Web of Science ®Google Scholar
• Lee M, Hong N, Lee YH, Kang ES, Cha BS, Lee BW. Elevated N-acetyl-β-d-glucosaminidase, a urinary tubular damage marker, is a significant predictor of carotid artery atherosclerosis in type 1 diabetes, independent of albuminuria: a cross-sectional study. J Diabetes Complications. 2018;32(8):777–783. doi:10.1016/j.jdiacomp.2018.05.019
   PubMed Web of Science ®Google Scholar
• Auta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34(4):975–981. doi:10.2337/dc10-1545
   PubMed Web of Science ®Google Scholar
• Weitgasser R, Schnoell F, Gappmayer B, Kartnig I. Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care. 1999;22(11):1882–1886. doi:10.2337/diacare.22.11.1882
   PubMed Web of Science ®Google Scholar
• Kopf S, Oikonomou D, Zdunek D, et al. Urinary n-acetyl-beta-d-glucosaminidase excretion: an indicator of neuropathy in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013;121(10):601–606. doi:10.1055/s-0033-1355384
   PubMed Web of Science ®Google Scholar
• Shimojo N, Kitahashi S, Naka K, et al. Comparison of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase activities for evaluation of microangiopathy in diabetes mellitus. Metabolism. 1987;36(3):277–280. doi:10.1016/0026-0495(87)90188-0
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6(11):891–900. doi:10.1016/S2213-8587(18)30052-4
   PubMed Web of Science ®Google Scholar
• Bikbov B, Purcell CA, Levey AS; GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. doi:10.1016/S0140-6736(20)30045-3
   PubMed Web of Science ®Google Scholar
• Laffel LM, Kanapka LG, Beck RW, et al; CGM Intervention in Teens and Young Adults with T1D (CITY) Study Group; CDE10. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2388–2396. doi:10.1001/jama.2020.6940
   PubMed Web of Science ®Google Scholar
• Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38(Suppl 1):S14–s19.
   PubMedGoogle Scholar
• García-Nieto V, García-Rodríguez VE, Luis-Yanes MI, Monge M, Arango-Sancho P, Garin EH. Renal tubular markers as screening tools for severe vesicoureteral reflux. Eur J Pediatr. 2019;178(4):525–531. doi:10.1007/s00431-019-03324-9
   PubMed Web of Science ®Google Scholar
• Kordonouri O, Hartmann R, Müller C, Danne T, Weber B. Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes. Horm Res. 1998;50(Suppl 1):23–27.
   PubMedGoogle Scholar
• Kato H, Takashima T, Kishikawa H, Emura S, Ohmori K. The significance of urinary N-acetyl-beta-D-glucosaminidase for predicting early stage diabetic nephropathy. Int J Clin Pract. 1997;51(8):489–490.
   PubMed Web of Science ®Google Scholar
• Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705–2712. doi:10.1093/eurheartj/ehr190
   PubMed Web of Science ®Google Scholar
• Ouchi M, Oba K, Saigusa T, et al. Association between pulse wave velocity and a marker of renal tubular damage (N-acetyl-β-D-glucosaminidase) in patients without diabetes. J Clin Hypertens. 2015;17(4):290–297. doi:10.1111/jch.12492
   Web of Science ®Google Scholar
• Solbu MD, Toft I, Lochen ML, Mathiesen EB, Eriksen BO, Melsom T. N-Acetyl-β-d-glucosaminidase does not enhance prediction of cardiovascular or all-cause mortality by albuminuria in a low-risk population. J Am Soc Nephrol. 2016;27(2):533–542. doi:10.1681/ASN.2014100960
   PubMed Web of Science ®Google Scholar